## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.5% below STRENGTH zone (4.0-10.0%); PEG 1.63 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Edgestream Partners L.P. Lowers Position in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251207T084921 | Somewhat-Bullish | Relevance: 99%
-  Edgestream Partners L.P. significantly reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 75.3% in the second quarter, selling over 12,000 shares. Despite this reduction, other institutional investors increased their holdings, and Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $206.57 for Cardinal Health. The company recently reported strong quarterly earnings, exceeding analyst estimates, and announced a quarterly dividend.

**2. Cardinal Health Target of Unusually Large Options Trading (NYSE:CAH)**
- Source: MarketBeat | 20251208T170818 | Bullish | Relevance: 99%
-  Cardinal Health (NYSE:CAH) recently experienced unusually high call option trading, with 7,495 call options acquired on Monday, a 74% increase from its average volume. Analysts maintain a "Moderate Buy" rating with an average price target of $206.57, following strong Q3 earnings where the company beat EPS and revenue expectations. Cardinal Health also announced a quarterly dividend of $0.5107 and provided positive FY2026 guidance.

**3. Amundi Sells 1,183,078 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251208T081427 | Somewhat-Bullish | Relevance: 99%
-  Amundi significantly reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by selling 1,183,078 shares in the second quarter, decreasing its holding by 62.2%. Despite this, other institutional investors like Marshall Wace LLP and GeoWealth Management LLC increased their positions. Cardinal Health (CAH) has a "Moderate Buy" consensus rating from analysts, recently beat Q3 earnings estimates, and maintains a $2.04 annual dividend.

**4. StoneX Group Inc. Purchases New Stake in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T123010 | Bullish | Relevance: 98%
-  StoneX Group Inc. initiated a new position in Cardinal Health, Inc. (NYSE:CAH) during the second quarter, acquiring 5,225 shares valued at approximately $878,000. This move is part of a broader trend of institutional investment, with several major firms increasing their stakes in CAH, bringing institutional ownership to 87.17%. Analysts maintain a "Moderate Buy" rating for Cardinal Health, with a consensus price target of $209.00, following the company's strong Q2 earnings report and positive FY2026 guidance.

**5. Jump Financial LLC Increases Stake in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251207T114359 | Bullish | Relevance: 98%
-  Jump Financial LLC significantly raised its stake in Cardinal Health, Inc. (CAH) by 2,257.6% in Q2, acquiring 183,114 shares valued at $30.76 million. This increased institutional interest aligns with positive analyst sentiment, as several firms raised price targets for CAH, leading to a "Moderate Buy" average rating. The company also surpassed quarterly earnings and revenue expectations, reporting $2.55 EPS and $64.01 billion in revenue, and declared a quarterly dividend of $0.5107.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.63 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.3B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.63 |
| Forward P/E | 18.0 |
| Current P/E | 20.2 |
| YoY Growth | 12.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.2% to -5.5% (-3.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.5pp (needs >4.0% for momentum thesis). AM_20 at -3.5% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.27x) but short-term weakness (below SMA20). MACD histogram bearish (-3.09), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.54% (CS: 11) | Weak |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | -3.09 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 1.091x | Above |
| vs SMA200 | 1.272x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.88
- **Stop Loss:** $190.58 (4.2% risk)
- **Target:** $207.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $11,932.80
- **Portfolio %:** 11.93%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*